4SC AG: 4SC to present results from the SENSITIZE study at the (virtual) 2021 ASCO Annual Meeting
Prof. Dr. Jessica C. Hassel, Principle Investigator of the SENSITIZE study at the University Hospital Heidelberg, German…
Prof. Dr. Jessica C. Hassel, Principle Investigator of the SENSITIZE study at the University Hospital Heidelberg, German…
4SC AG (4SC, FSE Prime Standard: VSC), today published the financial results of the 4SC Group for the financial year end…
Safety, tolerability and efficacy of resminostat in combination with S-1 chemotherapy will be investigated in various do…
Daily dosage of oral, anti-mitotic Eg5 inhibitor shows good safety and tolerability. Specifically, no peripheral neuropa…
Tägliche Dosierung des oralen antimitotischen Eg5-Hemmstoffs zeigt gute Sicherheit und Verträglichkeit. Insbesondere wur…
. - 4SC-205 is the only oral inhibitor of the Eg5 kinesin protein in clinical development worldwide. Eg5 plays a crucia…
4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for cancer…
. - Data from completed Phase I part of SHORE study in advanced colorectal cancer (CRC) to be presented at upcoming ASC…
. - 4SC-205 is the only oral inhibitor of the Eg5 kinesin in clinical development worldwide; the Eg5 protein plays a cr…
. - Overall survival (OS) data from Phase II SHELTER trial in advanced liver cancer (HCC) to be presented at 2012 ILCA…